Cargando…

SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica

The Caribbean region is lacking an assessment of the antibody response and side effects experienced after AstraZeneca COVID-19 vaccination (AZD1222). We examined severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) IgG levels and report the side effects no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leys, Ynolde E., Nwokocha, Magdalene, Walker, Jerome P., Butterfield, Tiffany R., Frater, Velesha D., Thompson, Tamara K., Anderson, Mark, Cloherty, Gavin A., Anzinger, Joshua J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128703/ https://www.ncbi.nlm.nih.gov/pubmed/35320778 http://dx.doi.org/10.4269/ajtmh.21-1128

Ejemplares similares

Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries
por: Sharun, Khan, et al.
Publicado: (2021)

Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam
por: Vu, Mai Thi, et al.
Publicado: (2021)

New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
por: Fragoso, Yara D, et al.
Publicado: (2022)

Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory
por: Yoon, Jong Pil, et al.
Publicado: (2022)

A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)

Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review
por: Ansari, B., et al.
Publicado: (2023)

Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) vaccine
por: Sindhu, Meenakshi, et al.
Publicado: (2023)

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023)

Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review
por: da Gama, Paulo Diniz, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021)

Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
por: Tran, Huyen, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021)

Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021)

AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021)

Ischemic stroke after AstraZeneca (Covid-19) vaccination
por: Alammar, Muath A.
Publicado: (2021)

Lipschütz ulcers after AstraZeneca COVID-19 vaccination()
por: Bracho-Borro, Maria, et al.
Publicado: (2023)

Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Denmark ceases roll out of AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine()
por: Crespo Burillo, J.A., et al.
Publicado: (2021)

Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
Publicado: (2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021)

AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
Publicado: (2021)

Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots
Publicado: (2021)

Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine
por: Morlidge, Clare, et al.
Publicado: (2021)

An analysis of AstraZeneca COVID-19 vaccine misinformation and fear mongering on Twitter
por: Jemielniak, D., et al.
Publicado: (2021)

Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021)

Vaccin AstraZeneca et événements thrombo-emboliques : l’EMA enquête
por: Manus, Jean-Marie
Publicado: (2021)

AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
Publicado: (2021)

Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fcnor3jogalnj0dcerjb1s0jnu